Magaldrate( Hydroxymagnesium Aluminate )
- Liquid 540 mg/5 mL
- Suspension 540 mg/5 mL
Neutralizes gastric acid, thereby increasing pH of stomach and duodenal bulb. Increases lower esophageal sphincter tone and inhibits smooth muscle contraction and gastric emptying.
Indications and Usage
Symptomatic relief of upset stomach associated with hyperacidity, including heartburn, gastroesophageal reflux, acid indigestion and sour stomach; relief of hyperacidity associated with peptic ulcer, gastritis, peptic esophagitis, gastric hyperacidity and hiatal hernia.
Severe renal dysfunction; hypophosphatemia; nausea; vomiting; severe abdominal pain; acute surgical abdomen; impaction; intestinal obstruction.
Dosage and AdministrationAdults
PO 480 to 1080 mg 4 times daily as needed or to aid in peptic ulcer healing or chronic reflux, give 1 h and 3 h after meals and at bedtime (7 doses/day).Children
PO 5 to 10 mg/dose every 3 to 6 h or 1 h and 3 h after meals and at bedtime for peptic ulcer.
Store at room temperature (59° to 86°F).
Decreased pharmacologic effect of iron.Ketoconazole
Decreased pharmacologic effect of ketoconazole.Nitrofurantoin
Decreased effects of nitrofurantoin.Penicillamine
Decreased pharmacologic effect of penicillamine.Quinidine
Increased pharmacologic effect of quinidine.Quinolones
Decreased pharmacologic effect of quinolones.Salicylates
Decreased pharmacologic effect of salicylates.Sodium polystyrene sulfonate
Concomitant use may cause metabolic alkalosis in patients with renal failure.Tetracyclines
Decreased pharmacologic effect of tetracyclines.
Laboratory Test Interactions
None well documented.
Diarrhea; constipation; intestinal obstruction; rebound hyperacidity.
Osteomalacia; bone pain; muscular weakness; malaise; decreased fluoride absorption; aluminum accumulation in serum, bone and CNS; milk-alkali syndrome.
Pregnancy category undetermined.
Use with caution in patients with renal function impairment to avoid hypermagnesemia and toxicity.
Use with care in patients with recent massive upper GI hemorrhage.
Nausea, vomiting, diarrhea, constipation, hypermagnesemia, hypophosphatemia.
- Instruct patient to take medication 1 and 3 h after meals and at bedtime.
- Warn patient not to take other medications within 2 h of antacid.
- Review proper use of suspension or tablet form.
- Advise patient to consult health care provider if problem recurs, if any symptoms that suggest bleeding occur (eg, black, tarry stools) or if patient has taken antacids for more than 2 wk.
Copyright © 2009 Wolters Kluwer Health.